Sanofi
Stock performance
History
Sanofi's roots trace to a pharmaceutical arm established by French oil company Elf Aquitaine in 1973, which grew through a series of mergers and acquisitions — most significantly combining with German group Hoechst's pharmaceutical business (Aventis) in 2004 to form Sanofi-Aventis, later simplified to Sanofi. The company built a broad portfolio spanning prescription medicines, vaccines, and consumer healthcare, and has more recently focused its research pipeline on immunology and specialty medicines while divesting slower-growth consumer-health assets to sharpen its focus on higher-margin pharmaceutical innovation.
Business model
Sanofi researches, develops, and markets prescription pharmaceuticals across immunology, oncology, rare diseases, and neurology, alongside one of the world's largest vaccine businesses (Sanofi Pasteur) supplying immunizations globally. Its revenue depends on sustained R&D investment to replace older drugs facing patent expiration with new patent-protected medicines, a dynamic common to all major pharmaceutical companies, while its vaccines division provides a steadier, less patent-cliff-exposed revenue stream.
Market position
Sanofi is the largest pharmaceutical company in France and one of the largest in the world by revenue, competing with global peers including Pfizer, Merck, Novartis, and AstraZeneca. It holds a particularly strong global position in vaccines, historically one of the top handful of vaccine makers worldwide, and has invested heavily in immunology drugs like Dupixent, one of its best-selling products, to drive growth.
Country impact
Sanofi is one of the largest companies in France and a cornerstone of the country's pharmaceutical and life-sciences industry, a sector the French government has repeatedly identified as a strategic priority, including public support for domestic vaccine-manufacturing capacity following supply concerns during the COVID-19 pandemic. It is a significant employer in French research and manufacturing roles.